No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in Mumbai, India, in 1949, Ipca Laboratories Limited operates as a pharmaceutical enterprise focused on developing and commercializing both active pharmaceutical ingredients (APIs) and finished pharmaceutical formulations. Its API offerings span critical therapeutic areas, including anti-hypertensive, anti-malarial, diuretic, DMARD (disease-modifying anti-rheumatic drugs), and anthelmintic applications. The company provides an extensive portfolio of generic and branded formulations tailored for a broad spectrum of medical conditions. These therapeutic segments include allergies, oncology (cancer drugs), anti-arthritic conditions, epilepsy, hypertension, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, urology, psychiatry, respiratory ailments, orthopedics, oral anti-diabetes treatments, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppression, hepatoprotection, helminthic infections, fever, and emollients/protectives. In addition to its significant presence within India, Ipca Laboratories also exports its diverse range of products globally.
www.ipca.comNo one on the platform currently holds IPCALAB.BO.
No tracked institution reports a position in IPCALAB.BO as of their last filing.
No one on the platform has traded IPCALAB.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 21.0% | 26.2% | 30.2% | — | — | — |
| Rev. Growth % | 7.9% | 12.2% | ||||
| Profit Margin % | 11.8% | 10.0% | 10.9% | |||
| Free Cash Flow Margin % | 5.0% | 5.8% | 6.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $110.1B | +14.0% | $60.00 | $54.72–$65.43 | — | 15 |
| 2028 | $123.0B | +11.7% | $70.20 | $62.60–$77.88 | — | 16 |
| 2029 | $136.6B | +11.1% | $81.10 | $73.07–$86.74 | — | 7 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $12.16 | $15.84 | +30.3% |
| 2026-05-29 | $10.07 | $11.80 | +17.2% |
| 2026-02-13 | $11.66 | $12.20 | +4.6% |
| 2025-11-13 | $10.72 | $13.10 | +22.2% |
| 2025-08-11 | $9.07 | $9.19 | +1.3% |
| 2025-05-28 | $8.77 | $8.74 | -0.3% |
| 2025-02-12 | $8.45 | $9.78 | +15.7% |
| 2024-11-13 | $9.00 | $9.05 | +0.6% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| IPCALAB.BOIpca Laboratories Limited | $1954.50 | -0.64% | $499.5B | — |
| AJANTPHARM.BOAjanta Pharma Limited | $3504.15 | -0.93% | $437.2B | — |
| AJANTPHARM.NSAjanta Pharma Limited | $3519.40 | -0.40% | $439.7B | — |
| COHANCE.BOCohance Lifesciences Limited | $428.50 | -2.96% | $163.6B | — |
| COHANCE.NSCohance Lifesciences Limited |
| $427.45 |
| -2.90% |
| $163.5B |
| — |
| GLAND.BOGland Pharma Limited | $2885.00 | -1.54% | $475.6B | — |
| GLAND.NSGland Pharma Limited | $2888.40 | -1.16% | $476.5B | — |
Source: Financial Modeling Prep · peers by sector/industry